A1 Pharmaceuticals Plc

Latest News >>

A1 Pharmaceuticals Plc finalist in the Havering Business Awards 2014A1 listed in Sunday Times Profit Track 100A1 Pharmaceuticals Plc wins the highest business award in East LondonA1 Pharmaceuticals Plc declared as a National Champion in the European Business Awards 2013 – 20142013 Essex Countrywide Business Awards – A1 is Growing Business of the YearA1 Pharmaceuticals Plc declared Finalists in the European Business Awards 2012A1 Pharmaceuticals Plc recognised in Queen’s Birthday honours list 2012National Sales Awards 2004 – Sales Professional of the Year AwardNational Business Awards 2009 – Growth Strategy of the Year AwardNational Business Awards 2009 – Entrepreneur of the Year FinalistsErnst & Young Entrepreneur of year Winner 2007National Business Awards 2010- Entrepreneur of the Year FinalistsChamber Award 2011 – Achievement in International BusinessSunday Times International Fast Track 100 (2011) and Fast Track 200 (2012)

A1 Pharmaceuticals Plc Financial Year 2018

30th October 2018

A1 Pharmaceuticals Plc file record accounts in 2018
In spite of the uncertainty and disruptive nature of the Brexit negotiations A1 Pharmaceuticals Plc have recorded the 3rd most profitable year in their 32 year history

Managing Director Gary Lewis is quoted as saying “this is no small feat considering that the immediate fallout of the EU referendum in June 2016 meant sterling was substantially weakened, which lead to a significant increase in cost of sales and a sharp fall in profits. It’s a reflection of our improving management, resilience and fortitude that in spite of a drop in overall annual sales of 6.5% pre tax net profit is up by a huge 18.7% on the previous year to £3.95M which is the 3rd highest in our long 32 year history. We still have got a long way to go, Brexit with-out doubt has set us back at least 4 years but I am now more confident of the future than I have been for several years and although I do not fear for the future of the company, I do fear for the future British economy”

“I believe we are at A1 firmly in a post referendum recovery cycle and our 1st QTR of 2019 is also projecting a healthy profit growth of circa 5%. I am confident that we can improve on this projected growth and our 2018 results if we can agree a free trade deal with the EU that would be likely to strengthen sterling and favour Sales on imports and indeed reduce the risks to the British and world economy.”

“ The most impressive result in this year’s accounts is the 110% increase in net assets to a record £14.4M in just 4 years. This substantial improvement in liquidity and the associated reduction in debt risk to our suppliers has been reflected in a record rise from a credit safe rating from 81/100 to a new record 95/100 while the recommended credit limit has risen by 35% to £1.55M.”

“This outstanding credit rating means that we are now in the elite 1% of companies in the UK for low debt risk. Co-founder /Director Carmen Lewis has worked hard with her team tirelessly to develop a culture where suppliers and employees are both paid faster than ever before. In these increasingly uncertain economic times, it’s prudent that companies invest in regular assessment and monitoring of both their customers and suppliers credit ratings. Regular assessment of your trading partners’ debt risk substantially mitigates the risk and severity of loss. At A1 Pharmaceuticals, we are sending out a strong message in this year’s accounts which says we are solid, safe and reliable”

« Back to News
Facebook Iconfacebook like buttonTwitter Icontwitter follow buttonThomasWilliamLewis